7,7-Dimethyl-2-pyridin-4-yl-5,7-dihydro-3H-imidazo[4,5-f]indol-6-one

ID: ALA25931

Chembl Id: CHEMBL25931

Cas Number: 100510-33-6

PubChem CID: 65867

Max Phase: Phase

Molecular Formula: C16H14N4O

Molecular Weight: 278.31

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Synonyms: Adibendan | Adibendan|100510-33-6|Adibendan [INN]|E87N3L27KX|7,7-dimethyl-2-pyridin-4-yl-1,5-dihydropyrrolo[2,3-f]benzimidazol-6-one|BM 14478|5,7-Dihydro-7,7-dimethyl-2-(4-pyridyl)pyrrolo(2,3-f)benzimidazol-6(3H)-one|Pyrrolo(2,3-f)benzimidazol-6(1H)-one, 5,7-dihydro-7,7-dimethyl-2-(4-pyridinyl)-|Adibendanum|UNII-E87N3L27KX|Adibendanum [Latin]|ADIBENDAN [MART.]|CHEMBL25931|SCHEMBL613156|SCHEMBL9832050|DTXSID30143358|TVLQBBHUNDMTEC-UHFFFAOYSA-N|AKOS040745489|BM-14478|NS00125516|EN300-18567985|Q156Show More

Canonical SMILES:  CC1(C)C(=O)Nc2cc3[nH]c(-c4ccncc4)nc3cc21

Standard InChI:  InChI=1S/C16H14N4O/c1-16(2)10-7-12-13(8-11(10)20-15(16)21)19-14(18-12)9-3-5-17-6-4-9/h3-8H,1-2H3,(H,18,19)(H,20,21)

Standard InChI Key:  TVLQBBHUNDMTEC-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA25931

    ADIBENDAN

Associated Targets(Human)

PDE4A Tclin Phosphodiesterase; PDE3 & PDE4 (301 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ATP2A2 Tchem Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (53 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Rattus norvegicus (775804 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Felis catus (3858 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Canis familiaris (36305 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SARS-CoV-2 (38078 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: YesAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 278.31Molecular Weight (Monoisotopic): 278.1168AlogP: 2.85#Rotatable Bonds: 1
Polar Surface Area: 70.67Molecular Species: NEUTRALHBA: 3HBD: 2
#RO5 Violations: HBA (Lipinski): 5HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: 11.19CX Basic pKa: 5.13CX LogP: 2.26CX LogD: 2.26
Aromatic Rings: 3Heavy Atoms: 21QED Weighted: 0.72Np Likeness Score: -0.59

References

1. Mertens A, Müller-Beckmann B, Kampe W, Hölck JP, von der Saal W..  (1987)  Nonsteroidal cardiotonics. 1. 2-Pyridyl-6,7-dihydro-3H,5H-pyrrolo[2,3-f]benzimidazol-6-ones, a novel class of cardiotonic agents.,  30  (8): [PMID:3612681] [10.1021/jm00391a004]
2. von der Saal W, Hölck JP, Kampe W, Mertens A, Müller-Beckmann B..  (1989)  Nonsteroidal cardiotonics. 2. The inotropic activity of linear, tricyclic 5-6-5 fused heterocycles.,  32  (7): [PMID:2544724] [10.1021/jm00127a015]
3. Forest MC, Lahouratate P, Martin M, Nadler G, Quiniou MJ, Zimmermann RG..  (1992)  A novel class of cardiotonic agents: synthesis and biological evaluation of 5-substituted 3,6-dihydrothiadiazin-2-ones with cyclic AMP phosphodiesterase inhibiting and myofibrillar calcium sensitizing properties.,  35  (1): [PMID:1310113] [10.1021/jm00079a022]
4. USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date, 
5. Ellen Van Damme.  (2021)  Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity,  [10.6019/CHEMBL4651402]